final action
on 27 Jun 2023
Last Applicant/ Owned by
10230 Jasper Avenue
Edmonton, Alberta
CA
T5J4P6
Serial Number
97590585 filed on 14th Sep 2022
Registration Number
N/A
Correspondent Address
Theodore R. Remaklus
Filing Basis
1. filed as use application
2. use application currently
Disclaimer
NO DATA
Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and deveRead More
Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies
31st Mar 2011
31st Mar 2011
Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates
31st Mar 2011
31st Mar 2011
Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies
31st Mar 2011
31st Mar 2011
Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection
31st Mar 2011
31st Mar 2011
Nucleic acid sequencers for scientific purposes
31st Mar 2011
31st Mar 2011
Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases
31st Mar 2011
31st Mar 2011
Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for use in the biotechnological industry
31st Mar 2011
31st Mar 2011
No 97590585
No Service Mark
No TORYS-97-122
Yes
Yes
No
No
No
No
No
No
26.01.09 -
Geometric figures, objects, humans, plants or animals forming or bordering the perimeter of a circle
26.01.18 -
Three or more concentric circles
26.01.21 -
Circles that are totally or partially shaded
The mark consists of the word "entos" and to the right three concentric rings of circles with the circles increasing in diameter from the inner ring to the outer ring.
| Status Date | Action Taken |
|---|---|
| 06th Apr 2024 | ASSIGNED TO LIE |
| 16th Nov 2023 | TEAS REQUEST TO DIVIDE RECEIVED |
| 16th Nov 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 27th Sep 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| 27th Sep 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| 27th Jun 2023 | NON-FINAL ACTION WRITTEN |
| 27th Jun 2023 | NON-FINAL ACTION E-MAILED |
| 27th Jun 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 26th Jun 2023 | ASSIGNED TO EXAMINER |
| 30th Sep 2022 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
